[Effect of epirubicin on the heart conduction system in patients with Hodgkin's disease].
24 patients (12 women and 12 men) aged 17 to 70 years with Hodgkin's disease in the clinical stages IIA-IVB were treated according to the polychemotherapeutic schemes containing epirubicin (epiDX). Using the 24-hour ambulatory ECC on the day before and the day of drug application as well as after completion of the therapy, heart rate, arrhythmias and conduction abnormalities were estimated. There was statistically insignificant decrease in heart rate (mean, minimal and maximal) on the day of epiDX administration and after therapy completion. Arrhythmias in form of supraventricular and ventricular extrasystoles including bigeminy and couplets of VES in one patient and two episodes of atrial tachycardia in another one on the day of drug injection were noticed. In 2 young women occurred interruption of sinus rhythm lasting longer than 3 sec., due to sinus arrest in one and due to 2:1 sinus exit block in the second one. The above mentioned disturbances were in majority of patients not associated with clinical symptoms. The authors conclude that the reduction in heart rate and SVES formation might be in the majority of patients neurogenic but in some of them as well as VES generation result from epiDX action.
Usnarska-Zubkiewicz
L
L
Katedry i Kliniki Hematologii i Chorób Rozrostowych Krwi A.M., Wrocławiu.
Sciborski
R
R
Nowosad
H
H
Grzelak
H
H
Kotlarek-Haus
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D001919:Bradycardia / Q000139:chemically induced* / Q000517:prevention & control; D005117:Cardiac Complexes, Premature / Q000139:chemically induced* / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D015716:Electrocardiography, Ambulatory; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged
D015251:Epirubicin